1+ week, 5+ day ago   (67+ words) Pharmaceutical Executive Exec on Execs: Compliance Burdens The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals FDA Approves Daraxonrasib as…...

2+ week, 3+ day ago   (57+ words) Why Global Science Innovation is Shifting to Asia Pharmaceutical Executive Pharmaceutical Executive Daily: FDA Approves Imaavy for wAIHA What Executives and Investors Are Looking for in Pharma Companies FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and…...

4+ week, 1+ day ago   (542+ words) As trust shifts from a stated value to an operating condition, pharmaceutical leaders face new expectations for how credibility is built, governed and sustained under continuous scrutiny. Since 2023, the environment in which pharma companies earn — and lose — trust has shifted…...

1+ mon, 10+ hour ago   (313+ words) Krieger Scientific’s founder and CEO discusses how various factors, such as siloed systems and misuse of AI, may be responsible for the increase of warning letters from FDA. In July of this year, Krieger Scientific issued a release addressing the…...

1+ mon, 1+ week ago   (293+ words) Incubate’s executive director discusses China’s rise in biotech and why the US’ best response may be to focus on its own issues. Earlier this year, a report from Pharmaceutical Executive detailed the ways in which China is becoming an essential…...

1+ mon, 1+ week ago   (228+ words) John Stanford, executive director at Incubate, explains the COINS Act debate: should Treasury restrict US biotech investment in China, and what happens to American leadership if it does. Earlier this year, a report from Pharmaceutical Executive detailed the ways in…...

1+ mon, 3+ week ago   (212+ words) Pharmaceutical Executive He characterizes the policy environment as notably bipartisan, with agreement across both political parties and the last administrations on several core principles: the United States needs better visibility into critical medicines, more secure domestic capacity for those products,…...

3+ mon, 1+ week ago   (301+ words) PharmExec.com An End-to-End Approach to Specialty Patient Services - Learn how Inizio Engage's hub model integrates a non-dispensing pharmacy, automation, and clinical navigators to reduce friction across the patient access journey. - Explain how field reimbursement teams use real-time data and…...

3+ mon, 1+ week ago   (481+ words) Prescryptive Health’s chief commercial officer discusses the results of a market access survey that asked industry executives about DTC models, affordability, and patient access. In a survey of Pharmaceutical Executive and Pharmaceutical Commerce readers, respondents were asked a series of…...

3+ mon, 4+ week ago   (125+ words) Pharmaceutical Executive Toragen’s partnership with the Bill & Melinda Gates Foundation highlights how global health priorities and commercial biotech strategy can align around one of the world’s deadliest HPV-driven cancers. In the third part of her interview with Pharmaceutical Executive, Sandra…...